Caribou Biosciences presenta novedades sobre terapias CAR-T en conferencia sanitaria

16 de mayo de 2026

Reportado por IA

Caribou Biosciences abordó el progreso de sus terapias CAR-T listas para usar durante una presentación en la Conferencia Global de Salud de Bank of America el 13 de mayo. La directora ejecutiva, Rachel Haurwitz, destacó los datos de fase I de dos programas destinados al linfoma y al mieloma múltiple.

La empresa está avanzando en el desarrollo de Vispa-cel, que se dirige a CD19 para el linfoma, y CB-011, que se dirige a BCMA para el mieloma múltiple. Ambos programas recibieron actualizaciones clínicas significativas a finales del año pasado, y los primeros resultados respaldan un potencial de mejor en su clase, señaló Haurwitz durante la sesión moderada por el analista Alec Stranahan.

CAR-T therapy achieves complete remission of three autoimmune diseases in German woman

9 de abril de 2026 Reportado por IA Imagen generada por IA

A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.

CAR-T cell therapy shows early promise for HIV control

A small study has found that CAR-T cell therapy may offer a new way to manage HIV over the long term. The approach, already used to treat certain cancers, involves engineering a patient’s own immune cells.

Bioinvent hosts kol event on ovarian cancer therapies

1 de junio de 2026 Reportado por IA

BioInvent International AB held a key opinion leader event on May 27, 2026, to discuss ovarian cancer treatments and TNFR2-targeted therapies.

Business

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Europe

CRIS Cancer to donate 3.6 million to Vega Oncotargets after controversy

Business

Syntara reports positive FDA feedback on amsulostat trial

Scientists develop antibodies to block widespread Epstein-Barr virus

Researchers at Fred Hutch Cancer Center have created human-like monoclonal antibodies that prevent Epstein-Barr virus (EBV) from infecting immune cells. Using mice engineered with human antibody genes, the team identified antibodies targeting viral proteins gp350 and gp42, with one fully blocking infection in lab models. The findings, published in Cell Reports Medicine, could lead to therapies for transplant patients at risk of EBV-related complications.

Oncolys president reflects on journey to world-first cancer treatment

18 de junio de 2026 Reportado por IA

Yasuo Urata, president of Oncolys BioPharma, reflected on the long development process after the company received approval for a viral therapy targeting esophageal cancer.

25 de junio de 2026 15:16